Sell the Golden Goose, to AMGN, BIIB, CELG, GILD, or to another good cash flow biotech co.
ACT technological patents have value, so ACT should sell some of them, if not the entire company. As a investor with several thousand invested, we need to see some payback. Amgen, Biogen Idec, Celgen, and Gilead Sciences are in a great cash flow position to partner with ACT for joint venture, and to explorer the new stem cell frontier of medicine. Action needs to take place this year.
WOW, all someone has to do is buy around 100M shares to be the majority owner in the company, probably even less than that, would do it, and it would only cost them about $7M to do so. So why hasen't anyone bought out ACT so far? And we know that there are venture capitalists out there always looking for the next big thing to buy, that along with a huge market for AMD & SMD cures, makes one think taht someone would be looking at buying ACT, yet no capitalist has done so, why? Maybe the answer is that that none of them believes that ACT's AMD & SMD treatments are going to work. And these folks have all the resources in the world to check this ACT out, so I guess they still don't believe in ACT's cure for blindess.
But our salvation is that new technologies have always been under estimated by those supposedly in the know, just look at Apple, Microsoft, and Dell, to see where these guys missed out on great innovations and opportunities.
FYI: Big Pharma does believe in ACT's technology, however they are waiting for the final trial (phase). At this stage, they are investigating and researching how to get a bigger bang for their investment (buck) into ACTC. They are evaluating if it can be a billion dollar (profitable) product in the long term, so they are studing their anticipated profit margins, and comparing the anticipated operating manufacturing costs, and analyzing if the venture will work.
If the trials are successful, ACTC will be worth considerably more than it would be with a JV or patent sales at this point. They anticipate enough cash flow to last through the trials. Most investors are in it for the long run and willing to wait for a larger payout (hopefully).